August 7th 2020
By Tony Hagen
Investigators set out to learn whether the imposition of out-of-pocket spending caps on specialty drugs would unleash a wave of drug spending and prompt payer policy change.
August 6th 2020
Originator biologics should be monitored as closely as biosimilars, according to Gary Lyman, MD, MPH, of the Hutchinson Institute for Cancer Outcomes Research.
In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.
August 5th 2020
By Skylar Jeremias
Teva Pharmaceutical Industries has expanded on its hopes for a biosimilar comeback with a commercialization deal with Alvotech, which could bring as many as 5 biosimilars to the US market.
Biosimilars have improved access to health care in India, but many effective new drugs are high priced and patented, and authors of a new study recommend interventions to make these available, too.
August 4th 2020
Biosimilar exports make up a hefty chunk of biologics and other drug exports from the Republic of Korea to the United States and Europe, according to a report.
An oncology practice administrator describes the careful calculus involved in balancing patient needs with the business side of biosimilars and cancer care.
Amid the confusion of the pandemic, fundamental business strategies are reshaping the biosimilar playing field, according to corporate earnings reports.
August 3rd 2020
By Deana Ferreri, PhD
Investigators speculate on why infliximab biosimilars don’t have a larger market share by now.
World Health Organization (WHO) prequalification of Celltrion Healthcare’s trastuzumab opens the door for more affordable access to care for patients with breast and gastric cancers.
